Please ensure Javascript is enabled for purposes of website accessibility

ImClone's Mysterious Plunge

By Bill Mann – Updated Nov 16, 2016 at 5:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors flee the stock the instant before it receives great news. Oops.

Fairly strange turn of events surrounding ImClone (NASDAQ:IMCL) today. The formerly scandal-plagued biotechnology company had a sudden spike downward in trading at about 1:45 p.m., shedding almost 20% of its market cap in a matter of minutes. The Nasdaq quickly halted trading in the stock, at a hair under $34 per share -- well below the $43.96 open.

News was imminent. Someone knew something. What was it? Did Martha Stewart sing? Is Sam Waksal coming back from prison to lead ImClone again? No, that couldn't be it. And Martha's travails at this point really only have an impact on her own company, Martha Stewart Living Omnimedia (NYSE:MSO).

ImClone has been waiting on news from the Food and Drug Administration as to whether its colorectal cancer drug, Erbitux, has been approved. It was supposed to hear by tomorrow. That must be it... the FDA must have rejected it, right? The people in the know were piling toward the exits!

Wrong. The news -- when it came out a few minutes later -- was in fact about Erbitux, but it wasn't bad. In fact, the FDA approved the drug under the its Accelerated Approval Program, which gives priority to promising drugs that address diseases for which insufficient therapies exist. Approval under this program means there have been positive efficacy results from tests conducted to date. With the approval, ImClone has its first commercial product, which will be distributed by Bristol-Myers Squibb (NYSE:BMY).

We'll see what happens to the shares when trading is reopened. I would suspect they would leap -- even though, at a $2.5 billion market capitalization, ImClone has plenty of market success already priced into its stock. People who hold biotech companies such as ImClone invest in the hope of approvals like the one today for Erbitux. With almost a million shares traded in the 15 minutes before the halt, more than a few people got to the last second before they panicked and ran. It looks like they were wrong.

If you're going to hold a lottery ticket like ImClone stock, you might as well hold it until all of the numbers have been read.

Bill Mann has no financial interest in any company mentioned in this article.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$70.71 (-0.81%) $0.58
Martha Stewart Living Omnimedia, Inc. Stock Quote
Martha Stewart Living Omnimedia, Inc.
MSO.DL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.